Hosted on MSN3mon
Taysha Gene Therapies files for $300M mixed shelf offering
Taysha Gene Therapies (NASDAQ:TSHA) filed a prospectus for a mixed shelf offering of up to $300 million. The preliminary prospectus is not an offer to sell. Filing Taysha Gene Therapies ...
pharmaphorum2y
Astellas makes another gene therapy play, takes stake in Taysha
The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene ...
Yahoo Finance23d
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on ...
Benzinga.com5mon
Taysha Gene Therapies Stock Price, Quotes and Forecasts | NASDAQ:TSHA | Benzinga
Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Avi Kapoor Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" Neurogene (NASDAQ:NGNE ...
Business Insider1mon
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies ...